Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Any amyotrophic lateral sclerosis in which the cause of the disease is a mutation in the ALS2 gene.
Features include always present findings: Spasticity; and common findings: Short stature, Dystonia, Distal muscle weakness, and Ataxia and others. 49 total HPO annotations.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Brain and nerves | 22 | Spastic dysarthria, Dystonia, Spastic gait |
Muscles | 9 | Distal muscle weakness, Proximal muscle weakness, Muscle weakness |
Arms and legs | 6 | Lower limb spasticity, Limb joint contracture, Hand muscle atrophy |
Bones and joints | 4 | Skeletal muscle atrophy, Limb joint contracture, Severe backward arching of the body (opisthotonus) |
Head and neck | 2 | Microcephaly, Spasticity of facial muscles |
Growth and development | 1 | Short stature |
Eyes | 1 | Nystagmus |
Kidneys and urinary system | 1 | Urinary incontinence |
Digestive system | 1 | Difficulty swallowing (dysphagia) |
Pathogenic variants in ALS2 are responsible for a retrograde degeneration of the upper motor neurons of the pyramidal tracts, leading to phenotypes on a clinical continuum ranging from infantile ascending hereditary spastic paraplegia (IAHSP) to juvenile forms without lower motor neuron involvement (juvenile primary lateral sclerosis [JPLS]) or with lower motor neuron involvement (juvenile amyotrophic lateral sclerosis [JALS]). An increasing number of individuals have been identified with biallelic pathogenic variants in ALS2 [, , , , , , , , , , , , , , , , , , , ]. The following description of the phenotypic features associated with this disorder is based on these reports. reviewed the clinical and genetic characteristics of 82 individuals described in the literature to July 2020.
Source: GeneReviews — "ALS2-Related Disorder"
ALS2 encodes alsin Rho guanine nucleotide exchange factor ALS2 (1,657 aa). May act as a GTPase regulator. Controls survival and growth of spinal motoneurons Highest expression in Brain Cerebellar Hemisphere (126.8 TPM) and Brain Cerebellum (115.6 TPM).
Amyotrophic lateral sclerosis type 2, juvenile is associated with mutations in the ALS2 gene on chromosome 2.
The ALS2 protein participates in RAB5 GEFs exchange GTP for GDP on RAB5, RAC1 GEFs activate RAC1, and RHOA GEFs activate RHOA pathways.
ALS2 is classified as a druggable target with score 0.0.
identified significant clinical heterogeneity, and no correlation between disease severity and affected domain or type of variant. Both IAHSP and JPLS have been associated with truncating ALS2 variants.
Source: GeneReviews — "ALS2-Related Disorder"
No consensus clinical diagnostic criteria for ALS2-related disorder have been published. ALS2-related disorder comprises a phenotypic continuum of three phenotypes previously thought to be distinct entities: infantile-onset ascending hereditary spastic paralysis (IAHSP), juvenile primary lateral sclerosis (JPLS), and juvenile amyotrophic lateral sclerosis (JALS). Suggestive Findings ALS2-related disorder should be suspected in individuals with the following clinical, electrophysiologic, and neuroimaging findings and family history. Clinical Findings • Childhood onset of progressive upper motor neuron involvement (spasticity affecting the legs and upper limbs) • Variably lower motor neuron involvement (muscle atrophy and sensory disturbances) • Later pseudobulbar involvement including speech • Preservation of cognitive function Electrophysiologic Findings shows the results of various electrophysiologic studies in the different phenotypes of ALS2-related disorders. Note that nerve conduction velocities, visual evoked potentials, and brain stem auditory evoked potentials are normal in all phenotypes. Table 1. Electrophysiologic Studies in ALS2-Related Disorder by Phenotype Study | Phenotype
IAHSP | JPLS | JALS |
|---|---|---|
MEP | Severe dysfunction of the corticospinal tracts1 | NA |
SSEP | Normal in early stages; abnormal in later stages | Poorly configured; normal central conduction |
EMG | No signs of denervation | No signs of denervation |
Source: GeneReviews — "ALS2-Related Disorder"
For a detailed discussion of HSP and the differential diagnosis of HSP, see the Hereditary Spastic Paraplegia Overview. The hereditary spastic paraplegias are clinically and genetically heterogeneous disorders characterized by insidiously progressive lower-extremity weakness and spasticity. Hereditary spastic paraplegia may be transmitted in an autosomal dominant, autosomal recessive, X-linked, or maternally inherited (mitochondrial) manner.
Source: GeneReviews — "ALS2-Related Disorder"
Genetic testing for ALS2 is available. Testing is considered confirmatory for diagnosis.
Biomarker and diagnostic research for amyotrophic lateral sclerosis type 2, juvenile has been reported in the published literature.
No approved treatments are currently available for amyotrophic lateral sclerosis type 2, juvenile. The disease remains an area of unmet medical need.
No clinical practice guidelines specifically for ALS2-related disorder have been published. Management is similar to that of persons with the wider range of amyotrophic lateral sclerosis (ALS), hereditary spastic paraplegia (HSP), and other neurodegenerative conditions. Evaluations Following Initial Diagnosis To establish the extent of disease and needs in an individual diagnosed with ALS2-related disorder, the evaluations summarized (if not performed as part of the evaluation that led to the diagnosis) are recommended. Table 3. Recommended Evaluations Following Initial Diagnosis in Individuals with ALS2-related Disorder
System/Concern | Evaluation | Comment |
|---|---|---|
Neurologic | By an experienced neurologist | For evidence of UMN, LMN, cranial nerve involvement Developmental assessment |
dislocation | By experienced orthopedist | Musculoskeletal/ |
ADL | Physical medicine rehab / PT/OT eval | To incl assessment of:; Gross motor fine motor skills; Mobility, ADL, need for adaptive devices; Need for PT (to improve gross motor skills) /or OT (to improve fine motor skills) |
Dysarthria | By speech language therapist | Consider need for alternative communication. |
Dysphagia | Gastroenterology / nutrition / feeding team eval |
Source: GeneReviews — "ALS2-Related Disorder"
Search ClinicalTrials.gov in the US and EU Clinical Trials Register in Europe for access to information on clinical studies for a wide range of diseases and conditions. Note: There may not be clinical trials for this disorder.
Source: GeneReviews — "ALS2-Related Disorder"
View trials for amyotrophic lateral sclerosis type 2, juvenile
Table 5.
Recommended Surveillance for Individuals with ALS2-related Disorder
System/Concern | Evaluation | Frequency
Neurologic
involvement | Neurologic exam to monitor progression of existing findings development of new findings | Annually or as needed
Development /
| Monitor developmental progress/educational needs.
| Monitor to assure early detection of scoliosis /or hip dislocation.
Musculoskeletal/
ADL | PT OT to monitor gross motor fine motor skills therapy/equipment needs
| Per speech language therapist
| Monitor nutrition, safety of oral feeding in those w/o gastrostomy tube.
Bladder
dysfunction | Per treating urologist
Bowel
dysfunction | Per treating clinician
Family support/
resources | Use of local resources, coordination of care
ADL = activities of daily living; OT = occupational therapy; PT = physical therapy
Source: GeneReviews — "ALS2-Related Disorder"
Phenotype severity distribution: 1 always present feature, 28 common features.
No clinical trials have been registered for amyotrophic lateral sclerosis type 2, juvenile.
15 publications have been identified in PubMed for amyotrophic lateral sclerosis type 2, juvenile. Research spans Case Report / Case Series (47%), Basic Science / Preclinical (20%), and Review / Meta-Analysis (13%).
Research Type | Count | % of Total |
|---|---|---|
Patient case studies | 7 | 47% |
Laboratory research | 3 | 20% |
Research summaries | 2 | 13% |
Disease patterns and progression | 2 | 13% |
Testing and diagnosis research | 1 | 7% |
Rodríguez-García V (2026). [PMID: 40544342](https://pubmed.ncbi.nlm.nih.gov/40544342/). *Amyotrophic lateral sclerosis & frontotemporal degeneration*. [Case Report / Case Series]
Allen MD (2026). [PMID: 41592170](https://pubmed.ncbi.nlm.nih.gov/41592170/). *Amyotrophic lateral sclerosis & frontotemporal degeneration*. [Review / Meta-Analysis]
Reza S (2026). [PMID: 41137727](https://pubmed.ncbi.nlm.nih.gov/41137727/). *Amyotrophic lateral sclerosis & frontotemporal degeneration*. [Epidemiology / Natural History]
Yoganathan S (2025). [PMID: 39424348](https://pubmed.ncbi.nlm.nih.gov/39424348/). *Neuropediatrics*. [Basic Science / Preclinical]
Eager KLM (2025). [PMID: 41131452](https://pubmed.ncbi.nlm.nih.gov/41131452/). *Genetics, selection, evolution : GSE*. [Basic Science / Preclinical]
Fu X (2025). [PMID: 40849231](https://pubmed.ncbi.nlm.nih.gov/40849231/). *Journal of neuromuscular diseases*. [Case Report / Case Series]
Po K (2024). [PMID: 39371851](https://pubmed.ncbi.nlm.nih.gov/39371851/). *Cureus*. [Case Report / Case Series]
Tazir M (2024). [PMID: 38702287](https://pubmed.ncbi.nlm.nih.gov/38702287/). *Revue neurologique*. [Review / Meta-Analysis]
Gowda VK (2024). [PMID: 38519722](https://pubmed.ncbi.nlm.nih.gov/38519722/). *Indian journal of pediatrics*. [Case Report / Case Series]
Mitsi E (2024). [PMID: 39730482](https://pubmed.ncbi.nlm.nih.gov/39730482/). *Scientific reports*. [Epidemiology / Natural History]
Data assembled from 6 of 12 sources · Last updated Sep 20, 2026, 5:31 PM UTC
Online Mendelian Inheritance in Man
Genetic and Rare Diseases Info Center
involvement | Ophthalmologic exam | Incl assessment of ocular movements Bladder |
dysfunction | Urologist | Assess for bladder spasticity w/frequency urgency of micturition. Bowel |
dysfunction | Gastroenterologist | Assess for signs symptoms related to immobility. Genetic |
counseling | By genetics professionals1 | To inform affected persons their families re nature, MOI, implications of ALS2-related disorder to facilitate medical personal decision making Family support/ resources |
Treatment of Manifestations in Individuals with ALS2-related Disorder Manifestation/Concern | Treatment | Considerations/Other UMN involvement (spasticity) / LMN involvement |
(weakness) | Orthopedics / physical medicine rehab / PT/OT | Stretching to help avoid contractures fractures; Consider need for orthotics, positioning mobility devices (e.g., motorized chairs), disability parking placard. Developmental/ |
educational issues | See . | — |
Scoliosis/hip dislocation | Per treating orthopedist | — |
Musculoskeletal/ADL | PT OT to promote mobility independence | — |
Dysarthria | Speech language therapy | Use of computer technologies devices adapted to facilitate writing voice communication |
Dysphagia | Gastrostomy tube placement may be required for persistent feeding issues. | Dietary supplements as needed to maintain weight |
Bladder dysfunction | Antispasticity medications, catheter | Per routine management of spastic bladder |
Bowel dysfunction | Monitor for constipation. | Stool softeners, prokinetics, osmotic agents, or laxatives as needed Family support/ resources |